Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: Int J Neuropsychopharmacol. 2014 Mar 20;17(8):1315–1320. doi: 10.1017/S1461145714000327

Figure 1.

Figure 1

Prior METH self-administration increases mBDNF immunoreactivity 24 h after the start of the last self-administration session (Panels A and B) and results in no change in SERT function (Panel C), and increases mBDNF immunoreactivity (Panel D) and SERT function (Panel E) 24 h after the binge exposure to METH. Rats self-administered METH (0.12 mg/infusion) or saline (10 µl/infusion) for 7 d (8 h/d). Twenty-four hours after the beginning of the final self-administration session, rats were sacrificed (Panel A, B, and C) or received METH (4 × 7.5 mg/kg/injection, s.c., 2-h intervals) or saline (1 ml/kg/injection, s.c., 2-h intervals) and were sacrificed 24 h later (Panels D and E), and BDNF immunoreactivity or SERT function was assessed in the hippocampus. Panel B: Representative β-Actin (~45 kDa), proBDNF immunoreactivity (~32 kDa) and mBDNF immunoreactivity (~14 kDa) in Saline (Left) and METH (Right) self-administering rats shown in Panel A. *p < 0.05 differs from all other groups